TY - JOUR
T1 - Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis
AU - Foulquier, Sebastien
AU - Boehm, Michael
AU - Schmieder, Roland
AU - Sleight, Peter
AU - Teo, Koon
AU - Yusuf, Salim
AU - Schumacher, Helmut
AU - Unger, Thomas
PY - 2014/6
Y1 - 2014/6
N2 - Background:In the Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease, all patients were at high cardiovascular risk, and a substantial proportion were hypertensive. We performed a post-hoc analysis to explore the hypothesis that telmisartan has a differential action in hypertensive vs. nonhypertensive patients.Methods:The primary four-fold endpoint (composite of cardiovascular death, myocardial infarction (MI), stroke, or hospitalization for heart failure), the secondary three-fold endpoint (cardiovascular death, MI, and stroke), the individual components, new onset of left ventricular hypertrophy (LVH), and new onset of albuminuria were analyzed.Results:There was no evidence for a significantly differential treatment effect of telmisartan in hypertensive and nonhypertensive patients for any endpoints, although the occurrence of the secondary three-fold endpoint was significantly lower in the telmisartan group (13.0%) compared with placebo (15.0%, P
AB - Background:In the Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease, all patients were at high cardiovascular risk, and a substantial proportion were hypertensive. We performed a post-hoc analysis to explore the hypothesis that telmisartan has a differential action in hypertensive vs. nonhypertensive patients.Methods:The primary four-fold endpoint (composite of cardiovascular death, myocardial infarction (MI), stroke, or hospitalization for heart failure), the secondary three-fold endpoint (cardiovascular death, MI, and stroke), the individual components, new onset of left ventricular hypertrophy (LVH), and new onset of albuminuria were analyzed.Results:There was no evidence for a significantly differential treatment effect of telmisartan in hypertensive and nonhypertensive patients for any endpoints, although the occurrence of the secondary three-fold endpoint was significantly lower in the telmisartan group (13.0%) compared with placebo (15.0%, P
KW - angiotensin receptor blocker
KW - hypertension
KW - myocardial infarction
KW - telmisartan
U2 - 10.1097/HJH.0000000000000154
DO - 10.1097/HJH.0000000000000154
M3 - Article
C2 - 24621807
SN - 0263-6352
VL - 32
SP - 1334
EP - 1341
JO - Journal of Hypertension
JF - Journal of Hypertension
IS - 6
ER -